Analysis for REGN

📈 Growth & Financial Trajectory

Eight quarters show revenue rising from about $3.03B in 2024 Q3 to $4.29B in 2026 Q2, a ~41% gain. Net income starts at about $1.34B and ends at about $1.30B, with fluctuations (peaks in 2025 and a mid-2026 dip). The path reflects sustained top-line growth with earnings volatility but a constructive trajectory.

💰 Margins & Cash Flow

Operating margins have remained robust, ranging roughly mid-20s to mid-30s percent; Q1 2026 margins are near 35.9%, with several quarters in the 30–36% zone. Positive cash flow from operating activities persisted across quarters; investing cash flows were negative as R&D and capex continued; financing varied, producing net cash flow that fluctuated between positive and negative.

🛡️ Balance Sheet & Liquidity

Assets ~ $41B and equity ~ $31B, with liabilities around $10B. Current assets versus current liabilities yield a strong liquidity cushion (current ratio ~ 3.3x). The balance sheet shows substantial equity support and conservative leverage.

⚠️ Key Drivers & Risks

• Drivers: robust antibody-based therapies and durable demand; pipeline progress and potential new approvals.
• Risks: regulatory/patent challenges and earnings volatility tied to trial outcomes and product mix.